NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free STXS Stock Alerts $1.87 0.00 (0.00%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$1.85▼$1.8950-Day Range N/A52-Week Range$1.33▼$3.29Volume20,074 shsAverage Volume301,252 shsMarket Capitalization$154.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Stereotaxis alerts: Email Address Stereotaxis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside137.5% Upside$4.50 Price TargetShort InterestHealthy1.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.45Based on 3 Articles This WeekInsider TradingAcquiring Shares$26,440 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.21) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.82 out of 5 stars 3.5 Analyst's Opinion Consensus RatingStereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStereotaxis has received no research coverage in the past 90 days.Read more about Stereotaxis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.65% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stereotaxis has recently increased by 1.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STXS. Previous Next 3.0 News and Social Media Coverage News SentimentStereotaxis has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Stereotaxis this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,440.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.52% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.21) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 9.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Stereotaxis Stock (NYSEAMERICAN:STXS)Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.Read More STXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STXS Stock News HeadlinesJune 18 at 5:15 AM | insidertrades.comPaul J. Isaac Acquires 7,000 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) StockJune 1, 2024 | insidertrades.comPaul J. Isaac Acquires 6,000 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) StockJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.May 29, 2024 | globenewswire.comPenn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart TreatmentMay 24, 2024 | finance.yahoo.comStereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory FrameworkMay 24, 2024 | globenewswire.comStereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory FrameworkMay 23, 2024 | seekingalpha.comStereotaxis Makes A Strategic Acquisition Bolstering Its FutureMay 22, 2024 | globenewswire.comFirst Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic TechnologyJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.May 15, 2024 | globenewswire.comStereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of AfricaMay 14, 2024 | finanznachrichten.deStereotaxis, Inc.: Stereotaxis Reports 2024 First Quarter Financial ResultsMay 14, 2024 | finanznachrichten.deStereotaxis, Inc.: Stereotaxis Announces Definitive Agreement to Acquire Access Point TechnologiesMay 14, 2024 | msn.comStereotaxis, Inc. (AMEX:STXS) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comStereotaxis Inc (STXS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth and ChallengesMay 13, 2024 | investorplace.comSTXS Stock Earnings: Stereotaxis Meets EPS, Misses Revenue for Q1 2024May 13, 2024 | bizjournals.comSt. Louis public company to acquire medical manufacturerMay 13, 2024 | marketwatch.comStereotaxis To Acquire Access Point TechnologiesMay 13, 2024 | globenewswire.comStereotaxis Reports 2024 First Quarter Financial ResultsMay 13, 2024 | globenewswire.comStereotaxis Announces Definitive Agreement to Acquire Access Point TechnologiesMay 12, 2024 | msn.comStereotaxis Q1 2024 Earnings PreviewApril 22, 2024 | globenewswire.comStereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024April 19, 2024 | investorplace.com3 Penny Stocks That Could Make a Big Comeback by the End of Q2April 17, 2024 | barrons.comStereotaxis Inc.April 10, 2024 | investorplace.com7 Penny Stocks That Could 5X by the End of 2024March 19, 2024 | markets.businessinsider.comStereotaxis Set for Breakout Growth: Buy Rating Affirmed Amidst Regulatory Advances and Robust FinancialsMarch 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 9, 2024 | seekingalpha.comMajor Regulatory Approvals Coming For Stereotaxis In The Next 10 MonthsSee More Headlines Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNYSEAMERICAN:STXS CUSIPN/A CIKN/A Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees122Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+140.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,710,000.00 Net Margins-73.32% Pretax Margin-73.32% Return on Equity-111.94% Return on Assets-45.63% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio1.79 Sales & Book Value Annual Sales$26.77 million Price / Sales5.77 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book9.35Miscellaneous Outstanding Shares82,640,000Free Float67,338,000Market Cap$154.54 million OptionableNot Optionable Beta1.53 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. David Leo Fischel C.A.I.A. (Age 37)C.F.A., C.P.A., M.B.A., CEO & Chairman Comp: $62.2kMs. Kimberly R. Peery (Age 55)CFO & Secretary Comp: $251.76kMr. Keith GallowayVice President of OperationsMs. Laura Spencer GarthGeneral Counsel & SecretaryMr. Guy JudkowskiEquity Portfolio ManagerKey CompetitorsAxoGenNASDAQ:AXGNZynexNASDAQ:ZYXISemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMEdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsPaul J IsaacBought 7,000 shares on 6/14/2024Total: $13,020.00 ($1.86/share)Paul J IsaacBought 1,000 shares on 5/31/2024Total: $1,960.00 ($1.96/share)Paul J IsaacBought 6,000 shares on 5/28/2024Total: $11,460.00 ($1.91/share)Virtu Financial LLCBought 11,739 shares on 5/20/2024Ownership: 0.040%Redmile Group LLCSold 93,645 shares on 5/16/2024Ownership: 4.029%View All Insider TransactionsView All Institutional Transactions STXS Stock Analysis - Frequently Asked Questions Should I buy or sell Stereotaxis stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STXS shares. View STXS analyst ratings or view top-rated stocks. What is Stereotaxis' stock price target for 2024? 2 equities research analysts have issued 1 year target prices for Stereotaxis' stock. Their STXS share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 137.5% from the stock's current price. View analysts price targets for STXS or view top-rated stocks among Wall Street analysts. How have STXS shares performed in 2024? Stereotaxis' stock was trading at $2.87 on January 1st, 2024. Since then, STXS stock has decreased by 34.0% and is now trading at $1.8950. View the best growth stocks for 2024 here. How were Stereotaxis' earnings last quarter? Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its earnings results on Monday, May, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The company earned $6.88 million during the quarter, compared to analyst estimates of $7.10 million. Stereotaxis had a negative trailing twelve-month return on equity of 111.94% and a negative net margin of 73.32%. Who are Stereotaxis' major shareholders? Stereotaxis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (4.03%), Vanguard Group Inc. (3.18%), Archon Capital Management LLC (3.05%), Essex Investment Management Co. LLC (1.45%), Virtu Financial LLC (0.04%) and GSG Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:STXS) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have...Allegiance Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.